atbtherapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$60M
- Investors
-
14
atbtherapeutics General Information
Description
Developer of antibody-based targeted therapy from plant cells designed to provide novel therapeutic treatment for patients with hard-to-treat cancer. The company offers antibodies with a new class of immunotherapy, which is a biologic format aimed at expanding the therapeutic window for treatment, enabling healthcare practitioners to use the combination of a new bioprocess with novel targeted therapies to help cancer patients.
Contact Information
Website
www.atbtherapeutics.comCorporate Office
- Novalis Science Park
- Rue De La Science, 8
- 6900 Aye
- Belgium
Corporate Office
- Novalis Science Park
- Rue De La Science, 8
- 6900 Aye
- Belgium
atbtherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | 01-Oct-2024 | $60M | Completed | Generating Revenue | ||
| 3. Seed Round | 17-Dec-2019 | Completed | Generating Revenue | |||
| 2. Seed Round | 01-Jan-2018 | $1.78M | $1.78M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
atbtherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Series A | ||||||||
| Class C | ||||||||
| Class B | ||||||||
| Class A | 5,082 | $9.84 | $9.84 | 1x | $9.84 | 0.13% | ||
| Ordinary | 124,000 | $6.1 | $6.1 | 1x | $6.1 | 3.27% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
atbtherapeutics Patents
atbtherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023322567-A1 | Humanized antibodies against cd79b | Pending | 08-Aug-2022 | ||
| EP-4568997-A1 | Humanized antibodies against cd79b | Pending | 08-Aug-2022 | ||
| US-20260152554-A1 | Humanized antibodies against cd79b | Pending | 08-Aug-2022 | ||
| WO-2024033362-A1 | Humanized antibodies against cd79b | Inactive | 08-Aug-2022 | ||
| EP-4479415-A1 | Recombinant immunotoxin comprising a ribosome inactivating protein | Pending | 17-Feb-2022 | A61K39/39558 |
atbtherapeutics Signals
atbtherapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Carbon ( Belgium ) | Venture Capital | Minority | ||
| Directorate General for Economy | Corporation | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| MRL Ventures Fund | Corporate Venture Capital | Minority | ||
| Société Fédérale de Participations et d'Investissement | Holding Company | Minority |
atbtherapeutics FAQs
-
When was atbtherapeutics founded?
atbtherapeutics was founded in 2017.
-
Where is atbtherapeutics headquartered?
atbtherapeutics is headquartered in Aye, Belgium.
-
What is the size of atbtherapeutics?
atbtherapeutics has 36 total employees.
-
What industry is atbtherapeutics in?
atbtherapeutics’s primary industry is Drug Discovery.
-
Is atbtherapeutics a private or public company?
atbtherapeutics is a Private company.
-
What is the current valuation of atbtherapeutics?
The current valuation of atbtherapeutics is .
-
What is atbtherapeutics’s current revenue?
The current revenue for atbtherapeutics is .
-
How much funding has atbtherapeutics raised over time?
atbtherapeutics has raised $66.1M.
-
Who are atbtherapeutics’s investors?
Carbon ( Belgium ), Directorate General for Economy, EQT Life Sciences, MRL Ventures Fund, and Société Fédérale de Participations et d'Investissement are 5 of 14 investors who have invested in atbtherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process